Circulating angiopoietin and Tie-2 levels in systemic sclerosis

Rheumatology International

Volumn 33, Issue 2, 2013, Pages 475-484

  Dunne, James V ^a   Keen, Kevin J ^b   Van Eeden, Stephan F ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF NORTHERN BRITISH COLUMBIA   (Canada)

Author keywords

Diffuse scleroderma; Endostatin; Limited scleroderma; Placental growth factor; Systemic scleroderma; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ENDOSTATIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENDOTHELIUM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TISSUE INJURY; VASCULAR DISEASE;

ADULT; AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTOR, TIE-2; SCLERODERMA, SYSTEMIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873999004     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2378-4     Document Type: Article

References (50)

1. LeRoy EC (1996) Systemic sclerosis: a vascular perspective. Rheum Dis Clin N Am 22(4):675-694
2. Sakkas LI (2005) New developments in the pathogenesis of systemic sclerosis. Autoimmunity 38(2):113-116
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202-205
4. Sivakumar B, Harry LE, Paleolog EM (2004) Modulating angiogenesis: more vs less. JAMA 292(8):972-977
5. Hattori T, Dias S, Hessig B, Hackett NR, Lyden D, Tateno M (2001) Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193(9):1005-1014
6. Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10(3):165-177
7. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K (1998) Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 139(6):1049-1051
8. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY (2002) Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci 102(2):187-194
9. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gasti G (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178-187
10. Benisty JI, McLaughlin VV, Landzberg MJ, Rich JD, Newburger JW, Rich S, Folman J (2004) Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 126(4):1255-1261
11. Choi J-J, Min D-J, Cho M-L, Min S-Y, Kim S-J, Lee S-S, Park K-S, Seo Y-I, Kim W-U, Park S-H, Cho C-S (2003) Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 30(7):1529-1533
12. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG (1991) Isolation of human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88(20):9267-9271
13. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, Paoletti I, Barra A, Tucci M, Parise G, Vincenti V, Granger HJ, Viglietto G, Persico MG (1997) Placental growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 76(4):517-531
14. Persico MG, Vincenti V, DiPalma T (1999) Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 237:32-40
15. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, Liberman TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclamsia. J Clin Invest 111(5):649-658
16. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD (1996) Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161-1169
17. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286(5449):2511-2514
18. Hegen A, Koidl S, Weindel K, Marme D, Augustin HG, Fiedler U (2004) Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vasc Biol 24(10):1803-1809
19. Fiedler U, Augustin HG (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27(12):552-558
20. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407(6801):242-248. doi: 10.1038/35025215
21. Michalska-Jakubus M, Kowal-Bielecka O, Chodorowska G, Bielecki M, Krasowsk D (2011) Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of disease. Rheumatology 50:746-755. doi: 10.1093/rheumatology/keq392
22. Noda S, Asano Y, Aozasa N, Akamata K, Yamada D, Masui Y, Tamaki Z, Kadono T, Sato S (2011) Serum Tie2 levels: clinical association with microangiopathies in patients with systemic sclerosis. J Eur Acad Dermatol Venereol. doi: 10.1111/j.1468-3083.2011.04012.x
23. Guiducci S, Distler O, Distler JHW, Matucci-Cerinic M (2008) Mechanisms of vascular damage in SSc-implications for vascular treatment strategies. Rheumatology 47:v18-v20
24. Kuwana M, Okazaki Y, Yasuoka H et al (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364(9434):603-610
25. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M (2010) Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 14(6a):1241-1254
26. Baron M, Buchignani M, Dunne J et al (2006) Reliability of the dermalite dermatoscope for nailfold capillaroscopy in systemic sclerosis. J Rheumatol 33(15):375
27. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E (1985) Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 6(2):359-365
28. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, Corretti MC, Hassoun PM (2009) Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Care Med 179:615-621
29. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21(3 Suppl 29):S42-S46
30. Valentini G, Silman AJ, Veale D (2003) Assessment of disease activity. Clin Exp Rheumatol 21(3 Suppl 29):S39-S41
31. R Development Core Team (2005) R: a language and environment for statistical computing R foundation for statistical computing, Vienna, Austria
32. Hothorn T, Hornik K, van de Wiel MA, Zeileis A (2008) Implementing a class of permutation tests: the coin package. J Stat Softw 28(8):1-23
33. Hummers LK, Hall A, Wigley FM, Simons M (2009) Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 36(3):576-582
34. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Haculla A, Devulder B (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthr Rheum 43(4):889-893
35. Hamaguchi Y, Hasegawa M, Tanaka C, Kumada S, Sato S, Takehara K, Fujimoto M (2010) Elevated serum placenta growth factor (PlGF) levels in patients with systemic sclerosis: a possible role in the development of skin but not lung fibrosis. J Dermatol Sci 58(3):229-231
36. Poon RT, Ho JW, Tong CS et al (2004) Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91(10):1354-1360
37. Dziankowska-Bartkowiak B, Waszcykowska E, Zalewska A, Sysa-Jedrzejowska A (2005) Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediat Inflamm 3:144-149
38. Distler O, del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay RE, Michel BA, Bruhlmann P, Muller-Ladner U, Gay S, Matucci-Cerinic M (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelian growth factor are a feature of earliest disease stages and are associated with the absence of fingertip ulcers. Arthr Res 4(6):R11. doi: 10.1186/ar596
39. Distler O, Distler JHW, Scheid A, Acker T, Hirth A, Rethage J, Michel BA, Gay RE, Müller-Ladner U, Matucci-Cerinic M, Plate KH, Gassmann M, Gay S (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors lead to insufficient skin angiogenesis in patients with systemic sclerosis. Cir Res 95(1):109-161
40. Witzenbichler B, Westermann D, Knueppel S, Schultheiss H-P, Tschope C (2005) Protective role of angiopoietin-1 in endotoxic shock. Circulation 111(1):97-105
41. Lee KW, Lip GYH, Blann AD (2004) Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor Tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110(16):2355-2360. doi: 10.1161/01.CIR.0000138112.90641.7F
42. David S, Kampers P, Lukasz A, Kielstein JT, Haller H, Danilo F (2009) Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/ pravastatin. J Hypertens 27(8):1641-1647
43. Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD (2008) Plasma levels of soluble Tie2 and VEGF distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol 52(5):387-393
44. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D (2001) Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 7(7):1992-1997
45. Siner JM, Bhandari V, Engle KM, Elias JA, Siegel MD (2009) Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis. Shock 31(4):348-353
46. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M (2001) Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 61(5):2145-2153
47. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284(5422):1994-1998
48. Reiss Y, Droste J, Heil M, Tribulova S, Schmidt MHH, Schaper W, Dumont DJ, Plate KH (2007) Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res 101(1):88-96
49. Hammes H-P, Lin J, Wagner P, Feng Y, vom Hagen F, Krzizok T, Renner O, Breier G, Brownlee M, Deutsch U (2004) Angiopoietin-2 causes pericyte dropout in the normal retina. Diabetes 53(4):1104-1110
50. Daly C, Pasnikowski E, Burova E, Wong V, Aldrich TH, Griffiths J, Ioffe E, Daly TJ, Fandl JP, Papadopoulos N, McDonald DM, Thurston G, Yancopoulos GD, Rudge JS (2006) Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci USA 103(42):15491-15496. doi: 10.1073/pnas.0607538103